| Project/Area Number |
26462423
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
藤本 清秀 奈良県立医科大学, 医学部, 教授 (50264867)
|
|---|
| Project Period (FY) |
2014-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 膀胱癌 / 診断マーカー / 癌幹細胞 / メチル化 / DNAメチル化 / 尿中剥離細胞 / がん幹細胞 / エピジェネティクス / エピジェネテイクス |
|---|
| Outline of Final Research Achievements |
High throughput DNA methylation analysis from the urine, revealed that aberrant DNA methylations of cancer stem cell genes were clearly classified between bladder cancer patients ’(T), after resection of bladder cancer patients’ (F), and healthy urines (H). In vitro study using epigenetic control agents study, aberrant DNA methylation of these cancer stem cell signal pathway genes significantly higher in higher malignant cancer cell line. However these aberrant DNA methylation were not detected with urine sediments. Then, we selected several aberrant DNA methylation loci from the analysis that showed quite significance between there groups. The validation cohort analysis, a total of 239 urine samples (T: 65, F:134, N:40), revealed that combined 5 genes aberrant DNA methylations could diagnose bladder cancer as 87.59% of sensitivity, and 78.96% of specificity.
|
